Pages that link to "Q35850620"
Jump to navigation
Jump to search
The following pages link to The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota (Q35850620):
Displaying 50 items.
- Gut Microbiota and Lifestyle Interventions in NAFLD (Q26749783) (← links)
- Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight (Q26752583) (← links)
- Diet, Microbiota, Obesity, and NAFLD: A Dangerous Quartet (Q26752614) (← links)
- Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. (Q30235846) (← links)
- Developmental origins of NAFLD: a womb with a clue (Q30241940) (← links)
- The Possible Role of Helicobacter pylori Infection in Non-alcoholic Fatty Liver Disease (Q33653828) (← links)
- Urinary Metabolomics in Pediatric Obesity and NAFLD Identifies Metabolic Pathways/Metabolites Related to Dietary Habits and Gut-Liver Axis Perturbations. (Q33749444) (← links)
- Oral arginine supplementation protects female mice from the onset of non-alcoholic steatohepatitis (Q33844302) (← links)
- Changes in the Intestinal Microbiome and Alcoholic and Nonalcoholic Liver Diseases: Causes or Effects? (Q38637349) (← links)
- Antibiotic perturbation of the murine gut microbiome enhances the adiposity, insulin resistance, and liver disease associated with high-fat diet (Q36002185) (← links)
- The metabolic role of the gut microbiota in health and rheumatic disease: mechanisms and interventions (Q36038992) (← links)
- Antibiotics as deep modulators of gut microbiota: between good and evil. (Q36105508) (← links)
- An Intestinal Microbiota-Farnesoid X Receptor Axis Modulates Metabolic Disease. (Q36136449) (← links)
- Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota (Q36148926) (← links)
- Personalized microbiome-based approaches to metabolic syndrome management and prevention (Q36175953) (← links)
- Alcohol, microbiome, life style influence alcohol and non-alcoholic organ damage (Q36246821) (← links)
- Mitochondrial gene polymorphisms alter hepatic cellular energy metabolism and aggravate diet-induced non-alcoholic steatohepatitis. (Q36740555) (← links)
- Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease. (Q36952218) (← links)
- Altered Fecal Microbiota Correlates with Liver Biochemistry in Nonobese Patients with Non-alcoholic Fatty Liver Disease (Q37195735) (← links)
- Non-alcoholic fatty liver and the gut microbiota (Q37215934) (← links)
- Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives (Q37538343) (← links)
- Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier (Q37572575) (← links)
- Overactivation of intestinal Sterol Response Element Binding Protein 2 promotes diet-induced non-alcoholic steatohepatitis (Q38642491) (← links)
- The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids (Q38659340) (← links)
- Gut Microbiota of Nonalcoholic Fatty Liver Disease (Q38742769) (← links)
- Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease (Q38806840) (← links)
- Gut microbiome and liver disease (Q38914215) (← links)
- The CF gastrointestinal microbiome: Structure and clinical impact (Q38962739) (← links)
- Liver inflammation and fibrosis (Q39065620) (← links)
- Intestinal microbiota and nonalcoholic steatohepatitis (Q39160020) (← links)
- Chronic opioid use is associated with altered gut microbiota and predicts readmissions in patients with cirrhosis (Q39169664) (← links)
- Association between serum soluble CD14 and IL-8 levels and clinical outcome in primary biliary cholangitis. (Q39176767) (← links)
- Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with HIV. (Q39238714) (← links)
- Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg. (Q39333658) (← links)
- Microbiome and NAFLD: potential influence of aerobic fitness and lifestyle modification (Q39363389) (← links)
- The gut microbiome and liver cancer: mechanisms and clinical translation. (Q39414187) (← links)
- Serum bile acid level and fatty acid composition in Chinese children with non-alcoholic fatty liver disease (Q40171343) (← links)
- Frequency and Risk Factors of Clostridium difficile Infection in Hospitalized Patients With Pouchitis: A Population-based Study (Q40293106) (← links)
- High-cholesterol diet does not alter gut microbiota composition in mice (Q40316798) (← links)
- Phyllanthus Niruri Standardized Extract Alleviates the Progression of Non-Alcoholic Fatty Liver Disease and Decreases Atherosclerotic Risk in Sprague-Dawley Rats (Q41195503) (← links)
- Markers of intestinal permeability are already altered in early stages of non-alcoholic fatty liver disease: Studies in children. (Q41575386) (← links)
- Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis (Q42000430) (← links)
- Short-Term Intake of a Fructose-, Fat- and Cholesterol-Rich Diet Causes Hepatic Steatosis in Mice: Effect of Antibiotic Treatment (Q42368248) (← links)
- The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis. (Q45071332) (← links)
- The nursing home elder microbiome stability and associations with age, frailty, nutrition and physical location. (Q46261848) (← links)
- Diets Alter the Gut Microbiome of Crocodile Lizards (Q46265269) (← links)
- Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease (Q46318841) (← links)
- Maternal modifiers of the infant gut microbiota: metabolic consequences (Q46329619) (← links)
- Immunoglobulin A and liver diseases. (Q46387163) (← links)
- Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in NAFLD mice. (Q46465311) (← links)